Jenburkt Pharmaceuticals Ltd.

740.00 +5.15 ▲0.7%

25 April 2024, 04:01:00 PM
Volume: 583

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.jenburkt.com
Market Cap 326.58 Cr.
Enterprise Value(EV) 270.91 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 55.40 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 13.36 Trailing Twelve Months Ending 2023-12
Industry PE 41.74 Trailing Twelve Months Ending 2023-12
Book Value / Share 307.73 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.40 Calculated using Price: 740.00
Dividend Yield 1.95 Period Ending 2023-03
No. of Shares Subscribed 0.44 Cr. 4,413,300 Shares
FaceValue 10
About Jenburkt Pharmaceuticals Ltd.
Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt Pharmaceuticals Ltd. Delivery

Delivered Qty
Traded Qty

Jenburkt Pharmaceuticals Ltd. Performance

1 Day
+0.70%
1 Week
-1.19%
1 Month
+5.74%
3 Month
-16.99%
6 Month
+16.98%
1 Year
+5.79%
2 Year
+20.08%
5 Year
+52.96%
10 Year
+644.47%

Jenburkt Pharmaceuticals Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 31.77 29.28 28.55 29.75 28.54 18.89 18.49 20.66 20.53
Return on Capital Employed (%) 42.35 40.17 39.26 41.99 36.9 25.73 23.83 26.89 26.8
Return on Assets (%) 18.4 18.13 20.1 22.36 21.99 14.37 14.68 16.95 17.33

Jenburkt Pharmaceuticals Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 33 40 54 61 77 80 98 117 122 130
Non Curr. Liab. 3 4 4 3 0 5 4 4 3 3
Curr. Liab. 24 14 18 13 25 20 18 21 16 16
Minority Int.
Equity & Liab. 61 58 76 78 103 104 120 143 141 149
Non Curr. Assets 12 13 13 12 13 15 40 67 60 66
Curr. Assets 49 45 64 66 90 90 80 76 81 83
Misc. Exp. not W/O
Total Assets 61 58 76 78 103 104 120 143 141 149

Jenburkt Pharmaceuticals Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 85 94 103 115 123 119 109 124 137 138
Other Income 2 3 3 3 3 4 4 5 5 5
Total Income 87 96 106 118 126 123 114 129 142 143
Total Expenditure -70 -77 -84 -91 -98 -99 -89 -97 -106 -108
PBIDT 17 19 23 27 28 24 24 32 35 36
Interest 0 0 0 0 0 -1 0 0 0 0
Depreciation -3 -2 -2 -2 -1 -2 -2 -2 -2 -2
Taxation -5 -6 -7 -8 -7 -6 -5 -8 -8 -8
Exceptional Items 0 0
PAT 10 11 14 17 20 15 17 22 25 24
Adjusted EPS 21 23 29 38 43 32 36 49 56 55

Jenburkt Pharmaceuticals Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 11 9 8 10 16 13 15 19 9 17
Cash Fr. Inv. 0 1 0 -10 1 -11 -3 -19 -1 3
Cash Fr. Finan. -7 1 -5 1 -18 -2 -11 -1 -6 -21
Net Change 5 11 2 1 -1 0 1 0 3 -1
Cash & Cash Eqvt 17 28 30 2 1 1 3 2 5 4

Jenburkt Pharmaceuticals Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 45.73 45.73 45.73 45.97 47.56 47.56 47.42 47.39 47.23
Public 54.27 54.27 54.27 54.03 52.44 52.44 52.58 52.61 52.77
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Jenburkt Pharmaceuticals Ltd. Announcements

Thu, 25 Apr 2024
Certificate Under Regulation 40(10) Of SEBI (LODR) Regulations 2015.
In compliance with Regulation 40(10) of SEBI (LODR) Regulations 2015 please find attached a certificate signed by a Partner of Nilesh Shah & Associates Practicing Company Secretaries under UDIN: F008063F000233728 for the FY starting from 01.04.2023 to 31.03.2024.
Wed, 24 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate and issuance of letter of Confirmation (Duplicate Share Certificate) in lieu thereof.
Mon, 15 Apr 2024
Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulatins 2015 For The FY Ended On 31St March 2024.
Compliance Certificate u/r 7(3) of the SEBI (LODR) Regulations 2015 for the FY ended on 31st March 2024.

Jenburkt Pharmaceuticals Ltd. Technical Scans

Wed, 24 Apr 2024
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
High Increase in 1 Month High Increase in 1 Month
High Decrease in 3 Months High Decrease in 3 Months
Closing Near 20 SMA Closing Near 20 SMA

Jenburkt Pharmaceuticals Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 364,830.88 1,520.15 +2.3%
Cipla Ltd. 113,471.29 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. 103,713.42 6,218.75 +4.5%
Divi's Laboratories Ltd. 101,959.84 3,843.80 +0.8%
Zydus Lifesciences Ltd. 95,944.41 951.25 +1.9%
Mankind Pharma Ltd. 95,926.91 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. 91,425.47 6,384.10 +1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 40.96 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-12 30.60 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.84 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-12 73.73 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-12 32.26 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-12 55.54 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.83 6,384.10 +1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.85 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-12 4.38 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.86 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-12 7.82 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.09 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-12 10.80 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.54 6,384.10 +1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,384.10 +1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,384.10 +1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,384.10 +1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,384.10 +1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,384.10 +1.6%

Jenburkt Pharmaceuticals Ltd. FAQ's

What is Jenburkt Pharma share price?

Can I buy Jenburkt Pharma shares now?

What is the Dividend Yield of Jenburkt Pharma?

What is the Market Cap of Jenburkt Pharma?

What are the key metrics to analyse Jenburkt Pharma?

What is the 52 Week High and Low of Jenburkt Pharma?

What is the trend of Jenburkt Pharma share price?